Saturday, July 16, 2016 11:08:20 AM
ALSO JUNO MENTIONED
Jul. 15, 2016 8:10 AM ET
About: GlycoMimetics (GLYC), SGEN, Includes: JUNO
William Meyers
Follow (1,085 followers)
Long only, tech, biotech, research analyst
Summary
•Acute Myeloid Leukemia is very difficult to treat successfully.
•Seattle Genetics SGN-CD33A started a Phase 3 trial.
•GlycoMimetics GMI-1271 started Phase 2 trial.
•There are other competitors, but it is unlikely AML will be 100% cured by any one therapy.
http://seekingalpha.com/article/3988622-aml-therapies-seattle-genetics-vs-glycomimetics?ifp=0&app=1
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM